ArticleJAMA neurology2022
Bringing Alzheimer Disease Testing and Results Disclosure Into the 21st Century Cures Act.
Article in JAMA neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- CONNECT4 APOE: A randomized trial of telephone versus real-time two-way videoconference for disclosure of APOE genotype results in cognitively unimpaired adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Trial
- Legal Protections to Mitigate Discrimination due to Neurodegenerative Biomarker Status.Neurology · 2026Review
- Impact of learning APOE genotype on cognitively unimpaired adults: a pre-screening cohort study of the Alzheimer's Prevention Initiative Generation Study 1.The lancet. Healthy longevity · 2025Article
- Applying recommendations for diagnostic disclosure of mild cognitive impairment and dementia: Practical guidance for clinicians.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Observational
- "There has to be more caring": patient and care partner experiences of the disclosure of amyloid-β PET scan results.Aging & mental health · 2025Article
- Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- 2024 Alzheimer's disease facts and figures.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum.Neurology · 2023Article
- Preclinical Alzheimer Disease and the Electronic Health Record: Balancing Confidentiality and Care.Neurology · 2022Article
- Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- Communicating and Using Dementia Risk Evidence.Journal of Alzheimer's disease : JAD · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.